Lonza launches GS Xceed gene expression system
Allows for faster generation of clonal cell lines
Lonza, a leader in gene expression and biopharmaceutical development of protein therapeutics, has launched the GS Xceed gene expression system.
This is the latest generation of Lonza’s GS System, which has already been used to create more than 100 high producing cell lines and 13 therapeutic drugs currently on the market.
The Swiss firm says the GS Xceed system has been shown to reduce cell line development timelines by up to six weeks, compared with the existing CHOK1SV based system and has achieved titres of up to 6g/L. Both emerging and established companies with protein therapeutics in their pipeline can access this new system by either a research evaluation agreement or a commercial licence. GS Xceed is also available worldwide, allowing multinational companies global access to the system in all pharmaceutical and biotechnology markets.
The key element of the new system is the CHOK1SV GS Knock-out host cell line, which is a derivative of Lonza’s suspension adapted CHOK1SV host cell line in which both alleles of the endogenous glutamine synthetase gene have been ‘knocked out’.
Cell lines are selected in Lonza’s Version 8 (v8) commercial platform process, which allows for faster future scale-up into a GMP manufacturing system. Successful cell line construction, selection and development are on the critical path to achieving first in human studies. By shortening the development timeline by up to 6 weeks, customers gain a significant advantage in their product development lifecycle.
